40 sites, access to more than 1.5 million patients, and over 150 active investigators. Shared technology, marketing, recruiting, business development, contracts, budgets, and standard operating procedures, among other things, are projected to significantly increase the operational services that IACT Health and LMC Manna Research currently provide to the sector.
Dr. Jeff Kingsley, CEO of IACT Health, expressed delight over the partnership. He said, “We are thrilled to join forces with such a highly-qualified and reputable research organization that brings such deep experience and a proven track record of delivering on their clinical trials year after year”. He added, “Both companies share a commitment to quality, safety, patient satisfaction, and customer service that will position us as the preferred option for pharmaceutical and biotech companies, Contract Research Organizations (CROs), patients, and providers alike.”
Located in the Southeast United States, IACT Health is the leading US network of wholly-owned clinical research sites. The company’s mission is to transform the research feild by carrying out research in standard healthcare and urgent and emergency care. This will result in exceptional clinical trial experiences, improved outcomes, and reduced risk and low cost of studies. LMC Manna Research, Canada’s leading clinical research network, offers pharmaceutical firms and contract research organizations (CROs) with a single point of contact for conducting clinical trials across a broad range of therapeutic areas.
Karri Venn, President of LMC Manna Research, expressed optimism over the collaboration. He said, “LMC Manna Research is excited about the opportunity to work with IACT Health’s talented team, who share our approach to integrated research sites and systems, and place strong emphasis on quality and patient experience”. He added, “Together, we will offer sponsors and CROs a single point of contact to perform their clinical studies across North America, while providing meaningful and strategic combined research operations across these two networks to create North America’s pre-eminent clinical research network.”
